ArticleLancet regional health. Americas2026
Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pivotal trials for ocrelizumab in multiple sclerosis (MS) excluded adults >55 years old. This study aimed to compare rates of infection and infection-related hospitalization between ocrelizumab-treated and unexposed older adults with MS. Methods: A retrospective cohort study was performed, analyzing the electronic medical records, June 2017-January 2026, at the Massachusetts General Hospital, comparing 800 older adults with MS who received at least 600 mg of ocrelizumab IV to 800 older adults who never received B-cell depleting therapies. Infection and related hospitalization rates were modeled using inverse probability of treatment weighting and negative binomial regression with person-time offsets. Findings: Among 1600 adults (n = 1111, 69.4% female; n = 1496, 93.5% White; median ages 64 (range 55-88) for ocrelizumab and 67 years (range 55-98) for unexposed), median follow-up was 3.5 vs. 8.2 years. There were 429 infection-related hospitalizations (164 ocrelizumab, 265 unexposed), 10 infection-associated deaths (2 ocrelizumab, 8 unexposed), and 4538 infections (1597 ocrelizumab, 2941 unexposed). After adjustment, ocrelizumab was associated with a higher infection-associated hospitalization rate (IRR 1.67; 95% CI 1.15-2.43; p = 0.008) and infections (IRR 1.42; 95% CI 1.20-1.68; p < 0.001). Higher disability and comorbidity independently increased the risk of both outcomes. Female sex was associated with a higher infection risk (IRR 1.36, 95% CI 1.12-1.64, p = 0.002), driven mostly by urinary tract infections, which accounted for 91.46% of the observed sex difference. Interpretation: In adults aged ≥55 years with MS, ocrelizumab was associated with higher rates of infection-related hospitalization and infections. Findings support individualized risk-benefit discussion, especially regarding UTIs in older patients of female sex, dedicated UTI monitoring and prevention protocols for older ocrelizumab-treated patients, and inclusion of this age group in future clinical trials. Funding: Investigator-initiated grant from Genentech.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.